Better prognosis for ER-negative breast cancer

Article

Recent advances in chemotherapy are helping to close the survival gap between women with estrogen-receptor (ER)–positive breast cancer and those with ER-negative disease, according to the results of a recent series of studies.

Recent advances in chemotherapy are helping to close the survival gap between women with estrogen-receptor (ER)–positive breast cancer and those with ER-negative disease, according to the results of a recent series of studies.

Investigators found that biweekly doxorubicin/cyclophosphamide plus paclitaxel lowers the rate of recurrence and death in women with node-positive, ER-negative disease by more than 50% compared with treatment with low-dose cyclophosphamide, doxorubicin, and fluorouracil (CAF).

They also confirmed that chemotherapy benefits women with ER-negative disease far more than it does women with ER-positive disease; 22.8% more women with ER-negative breast cancer survived to 5 years without a recurrence if they were receiving chemotherapy versus 7% of ER-positive counterparts. Improvements in overall survival were 16.7% for ER-negative patients and 4% for ER-positive ones.

Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006;295:1658-1667.

Recent Videos
Trina Mansour, MD
Negative pressure wound therapy reduces c-section infections and costs | Image Credit: doctors.valleyhealth.com.
Amy Valent DO, MCR, highlights new tech for prenatal diabetes management | Image Credit: linkedin.com.
Lisa Bayer, MD, MPH
Megan Wasson, DO, FACOG
Megan Cohen, MD, MPH, outlines 2024 CDC contraception guidelines | Image Credit: linkedin.com.
Wasson and Colak
Johanna Finkle, MD, weight loss specialist, OB/GYN, The University of Kansas Health System.
Navigating hormone therapy in high-risk menopause cases | Image Credit: © dhaj7-cepo.com.
Tia Welsh, MD, highlights breakthroughs in cervical cancer screening | Image Credit: doctors.valleyhealth.com.
Related Content
© 2025 MJH Life Sciences

All rights reserved.